The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More

The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administ...
Learn More

2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin D2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high intestin...
Learn More

A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More

An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and ...
Learn More

This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More

The present invention relates to methods of use of glycosyltransferases and related compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomol...
Learn More

It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at ris...
Learn More

A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administerin...
Learn More

This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefo...
Learn More

This invention relates to vitamin D compounds, and more particularly to 2-methylene-1 α,25-dihydroxy-18,19,21-trinorvitamin D3 (DJ-55) and to pharmaceutical formulations that include this compound. T...
Learn More

This invention relates to vitamin D compounds, and more particularly to 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 (SX-99) and to pharmaceutical formulations that include this compound. The inv...
Learn More

The invention provides 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“GC-3”), 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“HLV”), and re...
Learn More

This invention relates to vitamin D compounds, and more particularly to 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds such as 2α-methyl-19,26,27-trinor-(20S)-1α,25-dihydroxyvitamin D3 (“P...
Learn More

The present invention uses pharmaceutical preparations of Botulinum toxin to induce neurogenic atrophy to alter muscle volume and subsequently, facial contour. Reduction in lip volume is accomplished ...
Learn More

This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More

This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More

This invention provides methods for modulating cellular gene expression for genes operably linked to an NRSE element that is recognized by an NRSF transcriptional repressor, by changing the concentrat...
Learn More

This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More

This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.
Learn More

Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have i...
Learn More

The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft t...
Learn More

This invention relates to a composition of botulinum based pharmaceuticals used for therapeutic and cosmetic treatment. This invention offers an improvement on the prior art by eliminating the potenti...
Learn More

Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target reg...
Learn More

Chalazia and hordeola are the most common lesions occurring in the human eyelid, and often recurrences are managed by surgical intervention to remove fatty inclusions within the lid with associated in...
Learn More